Pathophysiology of meningococcal sepsis in children

European Journal of Pediatrics

Volumn 157, Issue 11, 1998, Pages 869-880

  De Kleijn, E D ^a   Hazelzet, J A ^a   Kornelisse, R F ^a   De Groot, R ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Children; Meningococcal infection; Pathophysiology; Sepsis; Treatment

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; ENDOTOXIN; PROCOAGULANT;

BLOOD VESSEL TONE; CAPILLARY LEAK SYNDROME; CHILD; ENDOTHELIUM LESION; FULMINATING PURPURA; HUMAN; IMMUNE RESPONSE; MENINGOCOCCEMIA; NEISSERIA MENINGITIDIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK;

BLOOD COAGULATION DISORDERS; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; ENDOTOXINS; FIBRINOLYSIS; HUMANS; LIPOPOLYSACCHARIDES; MENINGOCOCCAL INFECTIONS; SEPSIS; SHOCK, SEPTIC;

EID: 0031765491     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004310050958     Document Type: Review

References (143)

1. Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, Kudsk K, Bruining HA, Otto C, Tobin E, Zwingelstein C, Lesslauer W, Leighton A (1997) p55 Tumour necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 277:1531-1538
2. Aiuto LT, Barone SR, Cohen PS, Boxer RA (1997) Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crit Care Med 25:1079-1082
3. Baggiolini M, Walz A, Kunkel SL (1989) Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 84:1045-1049
4. Baumann H, Wong GG (1989) Hepatocyte-stimulating factor III shares structural and functional identity with leukemia-inhibitory factor. J Immunol 143:1163-1167
5. Beca J, Butt W (1994) Extracorporeal membrane oxygenation for refractorary septic shock in children. Pediatrics 93:726-729
6. Best C, Walsh J, Sinclair J, Beattie J (1996) Early haemodiafiltration in meningococcal septicaemia. Lancet 347:202
7. Bone RC (1991) The pathogenesis of sepsis. Ann Intern Med 115:457-469
8. Booy R, Nadel S, Hibberd M, Newport MJ (1997) Genetic influence on cytokine production in meningococcal disease. Lancet 349:1176
9. Boucek MM, Boerth RC, Artman M, Graham TP Jr, Boucek RJ Jr (1984) Myocardial dysfunction in children with acute meningococcemia. J Pediatr 105:538-542
10. Brandtzaeg P, Kierulf P, Gaustad P, Skulberg A, Bruun JN, Halvorsen S, Sorensen E (1989) Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 159:195-204
11. Brandtzaeg P, Mollnes TE, Kierulf P (1989) Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 160:58-65
12. Brandtzaeg P, Sandset PM, Joo GB, Ovstebo R, Abildgaard U, Kierulf P (1989) The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 55:459-70
13. Brandtzaeg P, Joo GB, Brusletto B, Kierulf P (1990) Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 57:271-278
14. Brandtzaeg P, Ovsteboo R, Kierulf P (1992) Compartmentalization of lipopolysaccharide production correlates with clinical presentation in meningococcal disease. J Infect Dis 166:650-652
15. Brandtzaeg P, Hogasen K, Kierulf P, Mollnes TE (1996) The excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation. J Infect Dis 173:647-655
16. Bucklin SE, Russell SW, Morrison DC (1994) Participation of IFN-gamma in the pathogenesis of LPS lethality. Prog Clin Biol Res 388:399-406
17. Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP (1990) Prognostic values of tumour necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis 161:982-987
18. Champion MP, Murdoch IA, Sajjanhar T, Marsh MJ (1996) Extracorporeal membrane oxygenation for refractory shock in fulminant meningococcal sepsis. Lancet 374:201-202
19. Chehimi J, Trinchieri G (1994) Interleukin-12: a bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. J Clin Immunol 14:149-161
20. Cohen J, Carlet J (1996) INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumour necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 24:1431-1440
21. Connolly DT (1991) Vascular permeability factor: a unique regulator of blood vessel function. J Cell Biochem 47:219-223
22. D' andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G (1993) Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor IL-12 synthesis in accessory cells. J Exp Med 178:1041-1048
23. de Boer JP, Wolbink GJ, Thijs LG, Baars JW, Wagstaff J, Hack CE (1992) Interplay of complement and cytokines in the pathogenesis of septic shock. Immunopharmacology 24:135-148
24. de Waal Malefyt R, Abrams J, Bennet B, Figdor CG, de Vries JE (1991) Interleukin 10 (IL-10) inhibits cytokine synthesis by-human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209-1220
25. Densen P (1991) Complement deficiencies and meningococcal disease. Clin Exp Immunol 86:57-62
26. Derkx B, Marchant A, Goldman M, Bijlmer R, van Deventer S (1995) High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 171:229-232
27. DeVoe IW (1982) The meningococcus and mechanisms of pathogenicity. Microbiol Rev 46:162-190
28. Fijnvandraat K, Derkx B, Peters M, Bijlmer R, Sturk A, Prins MH, van Deventer SJ, ten Cate JW (1995) Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 73:15-20
29. Finn A, Naik S, Klein N, Levinsky RJ, Strobel S, Elliott M (1993) Interleukin-8 release and neutrophil degranulation after pediatric cardiopulmonary bypass. J Thorac Cardiovasc Surg 105:234-241
30. Fisher JC, Dhainaut JF, Opal SM (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double blind, placebocontrolled trial. JAMA 271:1836-1843
31. Fourrier F, Lestavel P, Chopin C, Marey A, Goudemand J, Rime A, Mangalaboyi J (1990) Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Intensive Care Med 16:121-124
32. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P (1992) Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies . Chest 101:816-823
33. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104:882-888
34. Frank MM, Joiner K, Hammer C (1987) The function of antibody and complement in the lysis of bacteria. Rev Infect Dis 9:S537-S545
35. Frank MM, Fries LF (1991) The role of complement in inflammation and phagocytosis. Immunol Today 12:322-326
36. Frieling JT, Sauerwein RW, Wijdenes J, Hendriks T, van der Linden CJ (1994) Soluble interleukin 6 receptor in biological fluids from human origin. Cytokine 6:376-381
37. Frieling JT, van Deuren M, Wijdenes J, van der Meer JW, Clement C, van der Linden CJ, Sauerwein RW (1995) Circulating interleukin-6 receptor in patients with sepsis syndrome. J Infect Dis 171:469-472
38. Frieling JTM, van Deuren M, Wijdenes J, van Dalen R, Bartelink AKM, van der Linden CJ, Sauwerwein RW (1996) Interleukin-6 and its soluble receptor during acute meningococcal infections: effect of plasma or whole blood exchange. Crit Care Med 24:1801-1805
39. Galanos C, Rietschel ET, Luderitz O, Westphal O (1971) Interaction of lipopolysaccharides and lipid A with complement. Eur J Biochem 19:143-152
40. Gardlund B, Sjolin J, Nilsson A, Roll M, Wickerts CJ, Wretlind B (1995) Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis 172:296-301
41. Gerard C, Bruyns C, Marchant A, Abramowicz D, Vandenabeele P, Delvaux A, Fiers W, Goldman M, Velu T (1993) Interleukin 10 reduces the release of tumour necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 177:547-550
42. Gerard P, Moriau M, Bachy A, Malvaux P, Meyer Rd (1973) Meningococcal purpura: report of 19 patients treated with heparin. J Pediatr 82:780-786
43. Gerson WT, Dickerman JD, Bovill EG, Golden E (1993) Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate. Pediatrics 91:418-422
44. Girardin E, Grau GE, Dayer JM, Roux-Lombard P, Lambert PH (1988) Tumour necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. New Engl J Med 319:397-400
45. Giroir BP, Quint PA, Barton P, Kirsch EA, Kitchen L, Goldstein B, Nelson BJ, Wedel NI, Carroll SF, Scannon PJ (1997) Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal permeability-increasing protein in children with severe meningococcal sepsis. Lancet 350:1439-1443
46. Godin C, Caprani A, Dufaux J, Flaud P (1993) Interactions between neutrophils and endothelial cells. J Cell Sci 106:441-451
47. Goldman AP, Kerr SJ, Butt W, Marsh MJ, Murdoch IA, Paul T, Firmin RK, Tasker RC, Macrae DJ (1997) Extracorporeal support for intractable cardiorespiratory failure due to meningococcal disease. Lancet 349:466-469
48. Goldstein IM (1985) Host factors in pathogenesis: the complementsystem potential pathogenic role in sepsis. In: Root RK, Sande MA (eds) Septic shock. Churchill Livingstone, New York
49. Hack CE, Ogilvie AC, Eisele B, Eerenberg AJ, Wagstaff J, Thijs LG (1993) Cl-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med 19:S19-S28
50. Halstensen A, Pedersen SHJ, Haneberg B, Bjorvatn B, Solberg CO (1987) Case fatality of meningococcal disease in western Norway. Scand J Infect Dis 19:35-42
51. Hamburger SA, McEver RP (1990) GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 75:550-554
52. Haneberg B, Gutteberg TJ, Moe PJ, Osterud B, Bjorvatn B, Lehmann EH (1983) Heparin for infants and children with meningococcal septicemia. Results of a randomized therapeuticc trial NIPH Ann 6:43-47
53. Hart CA, Rogers TR (1993) Meningococcal disease. J Med Microbiol 39:3-25
54. Hathaway WW (1973) Heparin therapy in acute meningococcemia. J Pediatr 82:900-901
55. Hazelzet JA, van der Voort F, Lindemans J, ter Heerdt PG, Neijens HJ (1994) Relation between cytokines and routine laboratory data in children with septic shock and purpura. Intensive Care Med 20:371-374
56. Hazelzet JA, Risseeuw-Appel IM, Kornelisse RF, Hop WCJ, Dekker I, Joosten KFM, de Groot R, Hack CE (1996) Age-related differences in outcome and severity of DIC in children with septic shock and purpura. Thromb Haemost 76:932-938
57. Hazelzet JA, Kornelisse RF, van der Pouw-Kraan TCTM, Joosten KFM, van dor Voort E, van Mierlo G, Suur MH, Hop WCJ, de Groot R, Hack CE (1997) Interleukin-12 levels during the initial phase of septic shock with purpura in children: relation to severity of disease. Cytokine 9:711-716
58. Hazelzet JA, Kornelisse RF, van Mierlo G, van der Voort E, de Groot R, Hack CE (1997) Complement activation in children with septic shock and purpura: classical or alternative pathway. Shock 7:74
59. Hazelzet JA, Kornelisse RF, van Mierlo G, van der Voort F, de Groot R, Hack CE (1997) The importance of Cl-inhibitor in children with septic shock and purpura. Shock 7:12
60. Heinzel FP (1990) The role of IFN-gamma in the pathology of experimental endotoxemia. J Immunol 145:2920-2924
61. Heinzel FP, Rerko RM, Ling P, Hakimi J, Schoenhaut DS (1994) Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon. Infect Immun 62:4244-4249
62. Hesselvik JF, Blombäck M, Brodin B, Maller R (1989) Coagulation, Fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit Care Med 17:724-733
63. Heyderman RS, Klein NJ, Shennan GI, Levin M (1991) Deficiency of prostacyclin production in meningococcal shock. Arch Dis Child 66:1296-1299
64. Houston DS, Shepherd JT, Vanhoutte PM (1986) Aggregation human platelets cause direct contraction and endothelium-dependent relaxation of isolated canin coronary arteries: role of serotonin, thromboxane A2, and adenine nucleotides. J Clin Invest 78:539-544
65. Jansen PM, Van der Pouw Kraan TCTM, De Jong IW, Van Mierlo G, Wijdeness J, Chang AA, Aarden LA, Taylor Jr FB, Hack CE (1996) Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: relation to plasma levels of interleukin-10 and interferon-gamma. Blood 87:5144-5151
66. Keeley SR, Matthews NT, Buist M (1991) Tissue plasminogen activator for gangrene in fulminant meningococcaemia. Lancet 337:1359
67. Klein NJ, Shennan GI, Heyderman RS, Levin M (1992) Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J Cell Sci 102:821-832
68. Klein NJ, Heyderman RS, Levin M (1993) Management of meningococcal infections. Br J Hosp Med 50:42-49
69. Kohan DE (1994) Role of endothelin and tumour necrosis factor in the renal response to sepsis. Nephrol Dial Transplant 9:73-77
70. Kohler J, Heumann D, Garotta G, LeRoy D, Bailat S, Barras C, Baumgartner JD, Glauser MP (1993) IFN-gamma involvement in the severity of gram-negative infections in mice. J Immunol 151:916-921
71. Kornelisse RF, Hazelzet JA, Savelkoul HFJ, Hop WCJ, Suur MH, Borsboom ANJ, Risseeuw-Appel IM, van der Voort E, de Groot R (1996) The relationship between plasminogen activator inhibitor-1, proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. J Infect Dis 173:1148-1156
72. Kumar A, Parillo JE (1997) Septic myocardial dysfunction: role of cytokines and nitric oxide. In: Vincent JL (ed) Yearbook of intensive care and emergency medicine. Springer, Berlin Heidelberg New York
73. Kumar A, Thota V, Dee L, Olson J, Uretz F, Parillo JE (1996) Tumour necrosis factor alpha and inlerleukin 1 beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 183:949-958
74. Klippermann N, Inkelis SH, Saladino R (1994) The role of heparin in the prevention of extremity and digit necrosis in meningococcal purpura fulminans. Pediatr Infect Dis J 13:867-873
75. Lampugnani MG, Caveda L, Breviario F, Del Maschio A, Dejana E (1993) Endothelial cell-to-cell junctions. Structural characteristics and functional role in the regulation of vascular permeability and leukocyte extravasation. Baillieres Clin Haematol 6:539-558
76. Lantz M, Bjornberg F, Olsson I, Richter J (1994) Adherence of neutrophils induces release of soluble tumour necrosis factor receptor forms. J Immunol 152:1362-1369
77. Leclerc F, Hazelzet JA, Jude B, Hofhuis W, Hue V, Martinot A, van der Voort E (1992) Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases. Intensive Care Med 18:202-205
78. Leeuwenberg JF, Jeunhomme TM, Buurman WA (1994) Slow release of soluble TNF receptors by monocytes in vitro. J Immunol 152:4036-4043
79. Lefer AM (1987) Interaction between myocardial depressant factor and vasoactive mediators with ischemia and shock. Am J Physiol 252:R193-R205
80. Lehmann AK, Halstensen A, Sornes S, Rokke O, Waage A (1995) High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. Infect Immun 63:2109-2112
81. Loos M, Bitter-Suermann D, Dierich M (1974) Interaction of the first (C1), the second (C2) and the fourth (C4) component of complement with different preparations of bacterial lipopolysaccharides and with lipid A. J Immunol 112:935-940
82. Lowenstein CL, Dinerman JL, Solomon H, Snyder H (1994) Nitric oxide: a physiologic messenger. Ann Intern Med 120
83. Manco-Johnson MJ (1994) Disseminated intravascular coagulation and other hypercoagulable syndromes. Int J Ped Hematol Oncol 1:1-23
84. Marra MN, Wilde CG, Collins MS, Snable JL, Thornton MB, Scott RW (1992) The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol 148:532-537
85. Mathison JC, Tobias PS, Wolfson E, Ulevitch RJ (1992) Plasma lipopolysaccharide (LPS)-binding protein. A key component in macrophage recognition of gram-negative LPS. J Immunol 149:200-206
86. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR (1994) Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 121:1-5
87. Mercier JC, Beaufils F, Hartmann JF, Azema D (1988) Hemodynamic patterns of meningococcal shock in children. Crit Care Med 16:27-33
88. Monsalve F, Rucabado L, Salvador A, Bonastre J, Cunat J, Ruano M (1984) Myocardial depression in septic shock caused by meningococcal infection. Crit Care Med 12:1021-1023
89. Morrison DC, Kline LF (1977) Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS). J Immunol 118:362-368
90. Nadel S, Newport MJ, Booy R, Levin M (1996) Variation in the tumour necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis 174:878-880
91. Niklasson P, Lundbergh P, Strandell T (1971) Prognostic factors in meningococcal disease. Scand J Infect Dis 3:17-25
92. Nuijens JH, Huijbregts CC, Eerenberg-Belmer AJ, Abbink JJ, Strack van Schijndel RJ, Felt-Bersma RJ, Thijs LG, Hack CE (1988) Quantification of plasma factor XIIa-Cl-inhibitor and kallikrein-Cl-inhibitor complexes in sepsis. Blood 72:1841-1848
93. Nuijens JH, Eerenberg-Belmer AJ, Huijbregts CC, Schreuder WO, Felt-Bersma RJ, Abbink JJ, Thijs LG, Hack CE (1989) Proteolytic inactivation of plasma Cl-inhibitor in sepsis. J Clin Invest 84:443-450
94. Nuijens JH, Abbink JJ, Wachtfogel YT, Colman RW, Eerenberg AJ, Dors D, Kamp AJ, Strack van Schijndel RJ, Thijs LG, Hack CE (1992) Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med 119:159-168
95. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550-552
96. Opal S, Fischer CJ, Dhainaut J, et al (1997) Confirmatory interluekin-1 receptor antagonist tria in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 25:1115-1124
97. Osterud B, Flaegstad T (1983) Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost 49:5-7
98. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W (1985) A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 76:1539-1553
99. Philippé J, Offner F, Declerck PJ, Leroux-Roels G, Vogelaers D, Baele G, Collen D (1991) Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemost 65:291-295
100. Pixley RA, Cadena Rdl, Page J, Kaufman N, Wyshock EG, Chang A, Taylor FB, Colman RW (1993) The contact system contributes to hypotension but not to disseminated intravascular coagulation in lethal bacteremia. J Clin Invest 91:61-68
101. Pollack M (1992) Editorial response: blood exchange and plasmapheresis in sepsis and septic shock. Clin Infect Dis 15:431-433
102. Powars DR, Rogers ZR, Patch MJ, McGehee WG, Francis RB (1987) Purpura fulminans in meningococcemia: association with acquired deficiencies of protein C and S. N Engl J Med 317:571-572
103. Powars D, Larsen R, Johnson J, Hulbert T, Sun T, Patch MJ, Francis R, Chan L (1993) Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis 17:254-261
104. Pradier O, Gerard C, Delvaux A, Lybin M, Abramowicz D, Capel P, Velu T, Goldman M (1993) Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide. Eur J Immunol 23:2700-2703
105. Reeves JH, Butt WW (1994) Blood filtration in children with severe sepsis: safe adjunctive therapy. Intensive Care Med 21:500-504
106. Reinhart K, Wiegand-Lohnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J (1996) Assessment of the safety and efficacy of the monoclonal anti-tumour necrosis factor antibody-fragment. MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 24:733-742
107. Rivard GE, David M, Farrell C, Schwarz HP (1995) Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 126:646-652
108. Romano M, Serhan CN (1992) Lipoxin generation by permeabilized human platelets. Biochem 31:8269-8277
109. Ross SC, Rosenthal PJ, Berberich HM, Densen P (1987) Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J Infect Dis 155:1266-1275
110. Saez-Llorens X, Lagrutta F (1993) The acute phase host reaction during bacterial infection and its clinical impact in children. Pediatr Infect Dis J 12:83-87
111. Saez-Llorens X, McCracken GH Jr (1993) Sepsis syndrome and septic shock in pediatrics: current concepts of terminology, pathophysiology, and management. J Pediatr 123:497-508
112. Smith OP, White B, Vaughan D, Rafferty M, Claffey L, Lyons B, Casey W (1997) Use of protein-C concentrate, heparin and heamodiafiltration in meningococcus-induced purpura fulminans. Lancet 350:1590-1593
113. Stuber F, Petersen M, Bokelmann F, Schade U (1996) A genomic polymorphism within the tumour necrosis factor locus influences plasma tumour necrosis factor-alpha concentrations and outcome of patients with severe sepsis [see comments]. Crit Care Med 24:381-384
114. Takakuwa T, Endo S, Nakae H, Suzuki T, Inada K, Yoshida M, Ogawa M, Uchida K (1994) Relationships between plasma levels of type-II phospholipase A2, PAF-acetylhydrolase, leukotriene B4. complements, endothelin-1, and thrombomodulin in patients with sepsis. Res Commun Chem Pathol Pharmacol 84:271-281
115. Taylor FB, Chang A, Ruf W, Morrisey JH, Hinshaw L, Catlett R, Blick K, Edgington TS (1991) Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 33:127-134
116. Tesh VL, Vukajlovich SW, Morrison DC (1988) Endotoxin interactions with serum proteins relationship to biological activity. Prog Clin Biol Res 272:47-62
117. Thijs LG, Hack CH (1992) Role of the complement cascade in severe sepsis. In: Lamy M, Thijs LG (eds) Mediators of sepsis. Springer, Berlin Heidelberg New York
118. Trinchieri G (1994) Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84:4008-4027
119. Trinchieri G (1995) Interleukin-12: a proinflammatory cylokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13:251-276
120. Trinchieri G, Scott P (1994) The role of interleukin 12 in the immune response, disease and therapy. Immunol Today 15:460-463
121. van Deuren M, Santman FW, van Dalen R, Sauerwein RW, Span LF, van der Meer JW (1992) Plasma and whole blood exchange in meningococcal sepsis. Clin Infect Dis 15:424-430
122. van Deuren M, van der Ven-Jongekrijg J, Bartelink AK, van Dalen R, Sauerwein RW, van der Meer JW (1995) Correlation between proinflammatory cytokines and antiinftamniatory mediators and the severity of disease in meningococcal infections. J Infect Dis 172:433-439
123. van Zee KJ, Kohno T, Fischer E, Rock C, Moldawer LL, Lowry SF (1992) Tumour necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumour necrosis factor-alpha in vitro and vivo. Proc Natl Acad Sci USA 89:4845-4849
124. Varani J, Ward PA (1994) Mechanisms of neutrophil-dependent and neutrophil-mdependent endothelial cell injury. Biol Signals 3:1-14
125. Verheul AF, Snippe H, Poolman JT (1993) Meningococcal lipopolysaccharides: virulence factor and potential vaccine component. Microbiol Rev 57:34-49
126. Vieusseux M (1805) Memoire sur la maladie qui a regné à Genève au printemps de 1805. J Med Chir Pharm 11:163-182
127. Voerman HJ, Stehouwer CD, van Kamp GJ, Strack van Schijndel RJ, Groeneveld AB, Thijs LG (1992) Plasma endothelin levels are increased during septic shock. Crit Care Med 20:1097-1101
128. Voss R, Matthias FR, Borkowski G, Reitz D (1990) Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit. Br J Haematol 75:99-105
129. Waage A, Halstensen A, Espevik T (1987) Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1:355-357
130. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T (1989) The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 169:333-338
131. Walley KR (1997) Mechanisms of decreased cardiac function in sepsis. In: Vincent JL (ed) Yearbook of intensive care and emergency medicine. Springer, Berlin Heidelberg New York
132. Ward PA, Varani J (1993) Mechanisms of neutrophil-mediated injury. Clin Exp Immunol 93:2
133. Waring PM, Waring LJ, Metcalf D (1994) Circulating leukemia inhibitory factor levels correlate with disease severity in meningococeemia. J Infect Dis 170:1224-1228
134. Weiss J, Elsbach P, Olsson H (1978) Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphnuclear leucocytes. J Biol Chem 253:2664-2672
135. Westendorp RG, Brand A, Haanen J, van Hinsbergh VW, Thompson J, van Eurth R, Meinders EA (1992) Leukaplasmapheresis in meningococcal septic shock. Am J Med 92:577-578
136. Westendorp RG, Langermans JA, de Bel CE, Meinders AE, Vandenbroucke JP, van Furth R, van Dissel JT (1995) Release of tumour necrosis factor: an innate host characteristic that may contribute to the outcome of meningococcal disease. J Infect Dis 171:1057-1060
137. Westendorp RGJ, Langermans JAM, Huizinga TWJ, Elouali AH, Verweij CL, Boomsma DI, Vandenbrouke JP (1997) Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349:170-173
138. Wong VK, Hitchcock W, Mason WH (1989) Meningococcal infections in children: a review of 100 cases. Pediatr Infect Dis J 8:224-227
139. Wysocka M, Kubin M, Vieira LQ, Ozmen L, Garotta G, Scott P. Trinchieri G (1995) Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol 25:672-676
140. Zeni F, Tardy B, Vindimian M, Pain P, Gery P, Bertrand J (1995) Soluble Interleukin 6 receptor in patients with severe sepsis. J Infect Dis 172:607
141. Zenz W, Muntean W, Gallistl S, Zobel G, Grubbauer HM (1995) Recombinant tissue plasminogen activator treatment in two infants with fulminant meningococeemia. Pediatrics 96:44-48
142. Zenz W, Muntean W, Zobel G, Grubbauer HM, Gallistl S (1995) Treatment of fulminant meningococcemia with recombinant tissue plasminogen activator. Thromb Haemost 74:802-803
143. Ziegler EJ, Fisher CJ, Jr., Sprung CL, Straube RC, Sadolf JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN, et al (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324:429-436